Results also showed a decrease in the CXCL10 levels in PBMCs (3.79-fold) and U87i (2.78-fold) lysates in the BBB models with PBMCs from moderate AD patients versus BBB models with PBMCs from mild AD patients (Fig 4). The gene discussed is CXCL10; the disease is Alzheimer disease.